glp-1 receptor agonists and cancer risk in adults with obesity show anti-cancer benefits beyond weight loss GLP-1s may reduce cancer risk

GLP-1 gastroparesis emerges as a serious yet often overlooked complication for patients using these popular medications

[Accessed on 18.4.2015]

The exact mechanisms through which activation of THR improves MASH are still unclear but are known to control fat synthesis, regulate fatty acid oxidation, regulate cholesterol metabolism, improve mitochondrial function, and reduce inflammation and fibrosis

LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose

Exendin-4 degrades more slowly than the human form of GLP-1, lasting for hours instead of minutes

Furthermore, continuous pipeline advancements point to robust future expansion in this market